Thromboembolism at Biology Products
Thromboembolism at Biology Technology
Thromboembolism at Medicine News
ARIXTRA drug for venous thromboembolism
Venous
thromboembolism is a complication causing increased bleeding which occurs after an orthopedic surgery procedure. // Professor Clifford W. Colwell has reported in the Journal of Arthroplasty that by giving a dose of ARIXTRA drug to these patients who underwent orthopedic surgery the complications and amount of bleeding decreased. ARIXTRA drug which is called as FLEXTRA (Flexibili...
Researchers Find That Thromboembolism Can Be Safely Treated At Home
Researchers have stated to find in their study that blood clots can be effectively managed at the homes of the patients.// According to a study that was led by Clive Kearon, professor of medicine at McMaster University that has been published in the August 23 issue of JAMA, The Journal of the American Medical Association the treatment of blood clots in the deep veins of the legs or th...
New Guidelines for Diagnosis of Venous Thromboembolism
AAFP and ACP have released new clinical practice guidelines for diagnosis and management of venous
thromboembolism.// Venous
thromboembolism is a condition that causes clotting in the veins. Key elements of the diagnosis guideline include the use of clinical prediction rules to establish pretest probability of deep vein thrombosis or pulmonary embolism in a patient before...
Thromboembolism at Medicine Products
Venous Thromboembolism (VTE), Qualitative
Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories
Thromboembolism at Medicine Technology
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...
New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility
EXCLAIM is the First International Study to Show That ExtendedThromboprophylaxis Reduces VTE Risk in Acutely-ill Medical PatientsWith a Statistically Significant 44% PARIS, July 8, 2007 /PRNewswire-FirstCall/ --Sanofi-aventisannounced today the results of the EXCLAIM (EXtended CLinicalprophylaxis in Acutely Ill Medical patients) study, which showedthe benefit of extended prophylaxi...
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous
thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...
The Lancet Publishes PREVAIL Study Results Showing Lovenox
Superiority Over Unfractionated Heparin for Reducing the Risk of
Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Risk of Having a Venous
ThromboEmbolism (VTE) is Reduced by aSignificant 43% in Acute Ischemic Stroke Patients Treated WithClexane(R) / Lovenox(R) BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ --Sanofi-aventis announced the publication of the PREVAIL (Preventionof VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial inthe April 21st issue of The Lancet. The results of th...
Portola Pharmaceuticals Announces Positive Phase II Results for
PRT054021 for Prevention of Venous Thromboembolism Following Total
Knee Replacement Surgery
Data to be Presented at the XXI Congress of the InternationalSociety on Thrombosis and Haemostasis SOUTH SAN FRANCISCO, Calif., April 04, 2007 /PRNewswire/ --Portola Pharmaceuticals, Inc. today announced that it has receivedpositive results from EXPERT, a Phase II study of its oral FactorXa inhibitor, PRT054021, for the prevention of venous
thromboembolism (VTE) following total knee replac...
Thromboembolism at Medicine Dictionary